ETFs to Buy as Eli Lilly Beats Q1 Earnings, Lifts Outlook
Lilly(US:LLY) Zacks Investment Research·2024-05-01 16:01Eli Lilly and Company (LLY) posted mixed first-quarter 2024 earnings, beating earnings estimates but lagging on revenues. The pharmaceutical giant raised its outlook for 2024 on rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro.The stock jumped 6% in response to the earnings beat. Investors seeking to tap the opportune moment could bet on ETFs having the largest exposure to the drugmaker. These include iShares U.S. Pharmaceuticals ETF (IHE) , Horizon Kinetics ...